Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Jiaqi MaHarper Cancer Research Institute and the Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46656.ORCID 0000-0002-6298-0193
Cory M AyresHarper Cancer Research Institute and the Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46656.
Chad A BrambleyHarper Cancer Research Institute and the Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46656.
Bassant EldalyHarper Cancer Research Institute and the Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46656.ORCID 0009-0009-9532-8546
W W J Gihan PereraHarper Cancer Research Institute and the Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46656.ORCID 0000-0001-5114-1979
James A LazarHarper Cancer Research Institute and the Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46656.ORCID 0009-0008-5975-281X
Evgenii L KovriginHarper Cancer Research Institute and the Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46656.
Smita S ChandranImmuno-Oncology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Christopher A KlebanoffImmuno-Oncology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Brian M BakerHarper Cancer Research Institute and the Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46656.ORCID 0000-0002-0864-0964
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Structural biophysics and molecular design in cellular immunityR35GM118166 · NIGMS · UNIVERSITY OF NOTRE DAME · PI BAKER, BRIAN M · 2016 to 2025
$4.4M
Molecular mechanisms of T cell responses to a clonal neoantigen resulting from a mutated driver oncogene.R37CA259177 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Christopher Austin Klebanoff · 2021 to 2026
$3.1M
Mechanisms and manipulation of force dependent behavior in T cell biologyR01AI176665 · NIAID · UNIVERSITY OF NOTRE DAME · PI Brian M Baker, Brian D Evavold · 2023 to 2026
$3.0M
Novel cell therapy approaches for molecularly defined subsets of therapy-resistant melanomaR01CA286507 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Christopher Austin Klebanoff · 2023 to 2026
$1.8M
BIACORE T200 SPR FOR NOTRE DAME BIOPHYSICS INSTRUMENTATION CORE (BIC) FACILITYS10OD028553 · OD · UNIVERSITY OF NOTRE DAME · PI BAKER, BRIAN M · 2020 to 2020
$343k
HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI17665HHS | NIH | National Institute of General Medical Sciences (NIGMS) R35GM118166HHS | NIH | NCI | Division of Cancer Prevention, National Cancer Institute (DCP, NCI) R37CA259177NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA286507NCI NIH HHS R37 CA259177NIAID NIH HHS R01 AI176665NIGMS NIH HHS R35 GM118166NIH HHS S10 OD028553
6 · The paper itself
Abstract
T cell receptor (TCR) restriction by highly polymorphic major histocompatibility complex (MHC) proteins is a foundation of cellular immunity. Although the effects of MHC polymorphisms on peptide binding and selection are well established, how micropolymorphisms within MHC supertypes impact immune recognition is poorly understood. Here, we identified a mechanism through which the micropolymorphisms in two closely related HLA-A3 superfamily members govern TCR specificity. We previously showed that TCRs specific for a public neoantigen arising from a
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
HLA micropolymorphisms confine neoantigen conformational adaptability and guide T cell receptor selectivity. · full record | OpenQuestion